Board of Directors

anders

Anders Tullgren
Chairman of the Board

Anders holds a M. Sc in Pharmacy from Uppsala University. He has over 30 years of global experience in the pharmaceutical industry and has had senior leadership roles in the United States, Germany, France, the United Kingdom and the Nordic region. The latest role he left in 2017 was as President of the Intercontintal region of Bristol Myers Squibb with responsibility for over 30 countries, 5,000 employees and a turnover of over 20 billion. He is Board member of Trialbee AB, Sweden, Biotoscana Investments S.A., Symphogen AS, and BrandingScience Ltd, UK.

Chairman of the Board since 2018.

Shares: 32,857

Warrants: 49,285

Independent in relation to the company and company management and major shareholders

Saeid Esmaeilzadeh DSC_4068-Redigera-4

PROF. SAEID ESMAEILZADEH
Board Member

Saeid holds a Ph.D. in Materials Chemistry from Stockholm University. He is a serial entrepreneur having established and managed a range of research-intensive companies in various industries. In 2002 he became the youngest associate professor in Sweden. He has received many distinctions and awards for his research as well as for his achievements as an entrepreneur. Saeid is an experienced board member and since 2010 has been the CEO of Serendipity Innovations.

Board member since 2018,
former Chairman of the Board 2008-2018.

Shares: 712,088 (direct: 28,759, indirect: 683,329)

Non-independent in relation to the company and company management and non-independet in relation to the company major shareholders

Maris hartmanis_small

PROF. MARIS HARTMANIS
Board Member

Maris holds a Ph.D. degree in Biochemistry from the Royal Institute of Technology in Stockholm, where he also is an Associate Professor. He is a seasoned industrial executive and leader with almost 30 years of CEO, senior R&D management and Board of Director experience from the international Life Science area. His experience stems from large organizations, as well as entrepreneurial start-ups. Most recently he was the CEO of two Swedish public pharmaceutical companies.

Board member since 2015.

Shares: 7,500

Warrants: 2,250

Independent in relation to the company and company management and major shareholders

Karin-Wingstrand_small

KARIN WINGSTRAND
Board Member

Karin holds a M. Sc. in Pharmaceutical Science. Karin has a broad experience of the international pharmaceutical industry from senior positions within regulatory, pharmaceutical and analytical R&D, project leadership as well as clinical. Most recently Karin held the position of Global Head and Vice President of Clinical Development at AstraZeneca.

Board member since 2015.

Shares: 7,900

Warrants: 3,000

Independent in relation to the company and company management and major shareholders

Peter-Edman_small

PROF. PETER EDMAN
Board Member

Peter holds a Ph. D. in Pharmacy and associate professor in biochemistry. He has an extensive experience in drug development from the pharmaceutical industry and has held a number of senior research leadership positions within Orexo, Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia. He has also held a position as Associate Professor at the Swedish Medical Product Agency.

Board member since 2015.

Shares: 7,500

Warrants: 2,250

Independent in relation to the company and company management and major shareholders

DSC_9482-2

GIORGIO CHIRIVI
Board Member

Giorgio holds a M. Sc. in Economics and business administration from University Luigi Bocconi in Italy. He operates as Head of Mergers & Acquisitions at UBI Banca SpA. Giorgio also has a board assignment for Axxam SpA.

Board member since 2016.

Shares: 2,000

Warrants: 3,000

Independent in relation to the company and company management and major shareholders

Alessandro

ALESSANDRO SIDOLI
Board Member

Alessandro holds a M. Sc. in biology from Pavia University in Italy and operates as CEO of Axxam SpA. Alessandro also has board assignments for FEDERCHIMICA, Italian Association of Business Angels, ALISEI and Externautics SpA.

Board member since 2016.

Shares: 76,885

Warrants: 3,000

Convertibles: 13,221

Independent in relation to the company and company management and major shareholders

Committees

Remuneration committee

The following board members are members of the Remuneration committee:

Anders Tullgren
Saeid Esmaeilzadeh
Maris Hartmanis
Giorgio Chirivi

Transaction committee

The following board members are members of the Transaction committee:

Anders Tullgren
Saeid Esmaeilzadeh
Peter Edman
Alessandro Sidoli

Audit committee

The following board members are members of the Audit committee:
Giorgio Chirivi
Karin Wingstrand
Maris Hartmanis